The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature
Authors:
Open Access
- 16 March 2019
- journal article
- review article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 9 (2) , 373-381
Abstract
We review the literature evaluating certolizumab in psoriasis and report our experience of treatment outcomes in a joint dermatology and rheumatology clinic.Keywords
This publication has 25 references indexed in Scilit:
- Recent advances in understanding psoriasisF1000Research, 2016
- One SNP at a Time: Moving beyond GWAS in PsoriasisJournal of Investigative Dermatology, 2016
- Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Journal of Investigative Dermatology, 2015
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 TrialsNew England Journal of Medicine, 2014
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and PrevalenceJournal of Investigative Dermatology, 2013
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Etanercept Treatment for Children and Adolescents with Plaque PsoriasisNew England Journal of Medicine, 2008
- Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialThe Lancet, 2006
- The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safetyDermatologic Clinics, 2004
- Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialThe Lancet, 2001